Business Context and Reporting Period
This Form 8-K is filed by Mind Medicine (MindMed) Inc. (not Definium Therapeutics, Inc.) for the reporting period of September 13, 2022. The registrant is incorporated in British Columbia, Canada, and its common shares trade on The NASDAQ Stock Market LLC under the symbol MNMD. The filing addresses a specific corporate event regarding listing compliance.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a regulatory status update.
Material Changes
The material event reported is the Company's receipt of notice from the Nasdaq Listing Qualifications Office on September 13, 2022. The notice confirmed that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This resolves a previous deficiency regarding the stock's trading price.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing compliance issue. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the current trading price of MNMD to ensure continued compliance with Nasdaq minimum bid requirements.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the compliance timeline.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.